trending Market Intelligence /marketintelligence/en/news-insights/trending/Mjm1GR6Hk0BWFrfdALuDmg2 content esgSubNav
In This List

US FDA grants orphan status to OncoSec's cancer drug

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


US FDA grants orphan status to OncoSec's cancer drug

The U.S. Food and Drug Administration granted an orphan drug designation to OncoSec Medical Inc.'s pIL-12, known as tavokinogene telsaplasmid, for the treatment of unresectable metastatic melanoma.

Tavokinogene telsaplasmid is the active biologic agent in ImmunoPulse IL-12, the company's lead product candidate.

OncoSec said the designation will provide the company with eligibility for certain development incentives, including tax credits for clinical testing, exemption from a prescription drug user fee, and seven years of market exclusivity.

The company is starting a phase 2 trial of the product in combination with Keytruda in patients with metastatic melanoma following disease progression on previous treatment with an anti-PD-1 therapy.